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Summary
Background Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic
mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET expression as the disease
progresses to more advanced stages and to a castration resistant state. Methods 80 patients (pts) with asymptomatic
or minimally symptomatic mCRPC were assigned (2:1) to either tivantinib 360 mg PO BID or placebo (P). The
primary endpoint was progression free survival (PFS). Results Of the 80 pts. enrolled, 78 (52 tivantinib, 26 P)
received treatment and were evaluable. Median follow up is 8.9 months (range: 2.3 to 19.6 months). Patients treated
with tivantinib had significantly better PFS vs. those treated with placebo (medians: 5.5 mo vs 3.7 mo, respectively;
HR = 0.55, 95% CI: 0.33 to 0.90; p = 0.02). Grade 3 febrile neutropenia was seen in 1 patient on tivantinib while
grade 3 and 4 neutropenia was recorded in 1 patient each on tivantinib and placebo. Grade 3 sinus bradycardia was
recorded in two men on the tivantinib arm. Conclusions Tivantinib has mild toxicity and improved PFS in men with
asymptomatic or minimally symptomatic mCRPC.
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Introduction
Metastatic castration resistant prostate cancer (mCRPC)
is the lethal version of this common disease. Prostate
cancer reaches this point through the combined events
of metastasis and adaptation by the tumor to a low
testosterone environment. The overall survival of men
with mCRPC has improved over the past few years with the
introduction of several different agents with non-overlapping
mechanisms of action. [1–5] Despite this progress, further
improvement is needed as men with mCRPC still invariably
succumb to this disease.
C-MET and prostate cancer
Hepatocyte growth factor (HGF) and its receptor N-methyl-N
′-nitrosoguanidine human osteosarcoma transforming gene
(MET) seem to play important roles in the metastatic process
[6, 7] and its signaling is abnormal in a variety of malignancies
[8]. Serum HGF levels are higher in metastatic prostate cancer
than in localized tumors [9] and has been associated with
poorer outcomes. [10] Xenograft and in vitro data reveal that
MET expression increases following androgen deprivation
suggesting an association with the development of castrate
resistant disease. [11, 12]
Tivantinib
Tivantinib (ARQ 197; ArQule, Burlington, MA; Daichi-
Sankyo, Tokyo, Japan) is an orally available selective small
molecule that inhibits MET receptor tyrosine kinase with a
novel ATP independent binding (allosteric inhibitor) mecha-
nism, leading to inhibition of cell proliferation and induction
of apoptosis in MET-expressing cancer cells. [13] [14, 15]
Tivantinib has been found to have additional properties and
in some preclinical studies its anti-cancer properties were in-
dependent of the c-MET inhibition. [16] Together, these find-
ings supported the hypothesis that tivantinib would have ac-
tivity against mCRPC. We therefore performed a phase II
randomized placebo controlled trial of tivantinib in men with
asymptomatic or minimally symptomatic mCRPC.
Patients and methods
Eligibility criteria
Eligible men were required to have metastatic histologically
confirmed prostate adenocarcinoma, castrate testosterone lev-
el (<50 ng/dL), to be asymptomatic or minimally symptomatic
(no symptoms attributable to prostate cancer greater than
Grade 1), ECOG ≤2, and PSA ≥ 2 ng/ml. Prior treatment with
sipuleucel- T and abiraterone acetate were allowed. Prior che-
motherapy was not allowed unless used in a perioperative
setting and completed >6 months prior to enrollment.
Progressive disease at study entry was required and defined
as two successive rises in PSA separated at least by one week,
appearance of two or more new lesions on bone scan, > 20%
objective increase in size of target lesion. This is consistent
with Prostate Cancer Working Group 2 guidelines (PCWG2)
for trials in advanced prostate cancer. [17] Bone targeting
agents such as zoledronic acid or denosumab were permitted
provided patients began therapy prior to study entry. Normal
organ and bone marrow function were required. Exclusion
criteria included radiotherapy within 4 weeks, uncontrolled
intercurrent illness, known brain metastasis, history of myo-
cardial infarction or unstable angina within 6 months, history
of severely impaired lung function, active liver disease, poorly
Fig. 1 CONSORT diagram
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controlled diabetes, or impairment of gastrointestinal function.
Institutional review board approval was obtained for all study
procedures at each participating site. Each patient provided
written informed consent.
Treatment plan
Participants were stratified based on prior treatment with
abiraterone acetate and sipuleucel-T and randomly allocated
Table 1 Baseline Characteristics
Characteristic Overall
N = 78
Tivantinib
N = 52
Placebo
N = 26
P-value
Age at study entry
Median (range)
67 (43–85) 67 (43–84) 66.5 (48–85) 0.93
Race
Asian 1 (1%) 1 (2%) 0 0.015
African American 8 (10%) 2 (4%) 6 (23%)
Caucasian 69 (88% 49 (94%) 20 (77%)
Ethnicity
non-Hispanic 75 (96%) 49 (94%) 26 0.55
unknown 3 (4%) 3 (6%) 0
ECOG PS
0 65 (83%) 42 (81%) 23 (88%) 0.53
1 13 (17%) 10 (19%) 3 (12%)
Gleason Score
< 7 9 (13%) 5(12%) 4 (16%) 0.25
7 17 25%) 10 (23%) 7 (29%)
> 7 41 (61%) 28(65%) 13(54%)
missing 11 9 2
PSA
median (range) 16.75 (2.2 to 868) 13.6 (2.3 to 868) 26.7 (2.2 to 579) 0.28
Alk phos
median (range) 80 (16 to 423) 80.5 (41 to 423) 78 (16 to 322) 0.90
missing 1 0 1
LDH
median (range) 192 (111 to 770) 186 (126 to 770) 196 (111 to 467) 0.89
missing 5 4 1
Hemoglobin
median (range) 13 (10.1 to 38.9) 13.1 (10.6 to 38.9) 12.9 (10.1 to 14.5) 0.53
Bone involvement
yes 50 (64%) 32 (62%) 18 (69%) 0.50
no 28 (36%) 20 (38%) 8 (31%)
Lymph node involvement
yes 17 (22%) 8 (15%) 9 (35%) 0.052
no 61 (78%) 44 (85%) 17 (65%)
Lung involvement
yes 5 (6%) 2 (4%) 3 (12%) 0.33
no 73 (94%) 50 (96%) 23 (88%)
Other organ involvement*
yes 12 (15%) 9 (17%) 3 (12%) 0.74
no 66 (85%) 43 (83%) 23 (88%)
Prior Treatment
Sipuleucel-T
yes 24 (31%) 16 (31%) 8 (31%) 0.999
no 54 (69%) 36 (69%) 18 (69%)
Abiraterone
yes 23 (29%) 16 (31%) 7 (27%) 0.73
no 55 (71%) 36 (69%) 19 (73%)
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at a ratio of 2:1 to receive tivantinib or placebo in a double-
blind fashion. Patients received twice-daily dosing of 360 mg
tivantinib by mouth or matched placebo. One cycle was
28 days. At the time of disease progression, the blind could
be broken and those assigned to the placebo arm were allowed
to cross over to tivantinib. At the time of the trial conduct,
abiraterone acetate was approved only in the post-docetaxel
setting, and neither enzalutamide nor radium223 were ap-
proved. Therefore, placebo in this clinical setting was felt to
be appropriate.
Efficacy outcome measures
We used PCWG2 guidelines to define disease progression
which included need for palliative radiation or surgery,
RECIST 1.1 defined progression, the appearance of ≥2 new
bone lesions on Tc99MDP bone scan (with instructions for
recognizing flare). Investigator determined clinical deteriora-
tion was also considered progression. Rising PSA levels alone
while on study drug were not considered disease progression.
Toxicity was evaluated using National Cancer Institute
Common Toxicity Criteria (version 4.0).
Pretreatment and follow-up evaluations
At baseline, participants underwent complete history, physical
examination and laboratory testing. Baseline imaging was
completed ≤4 weeks prior to start of treatment. Patients were
evaluated every 4 weeks with repeat examination, safety as-
sessment and standard laboratory testing. Whole body bone
imaging, CT of abdomen/pelvis and chest X-ray were per-
formed every 12 weeks or as needed for symptoms suggestive
of disease progression.
Statistical considerations
The primary endpoint in this trial was to compare the PFS of
tivantinib vs placebo. This was defined as the time from study
entry (start of blinded treatment) to the date of documented
progression and/or death, censoring alive and progression-free
patients at their last follow-up date. In this trial, the proposed
sample size of 78 eligible and evaluable patients (26 in the
placebo arm, 52 in the tivantinib arm) provided 90% power to
detect an improvement from 3 months median PFS with pla-
cebo to a median PFS of at least 6 months with the tivantinib
treatment, and a Type I error rate of 0.10 was assumed for this
one-sided test. This sample size was based on a log-rank test
calculation using the R statistical program (gsDesign package,
R version 2.11.1).
Since this was a phase II trial with a direct comparison
between the treatment arm and a placebo-control arm, we
relaxed the Type I error constraint to 0.10. [18] Progression
free survival curves based on observed data were constructed
using the Kaplan-Meier method, and Cox proportional
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hazards model was used to estimate the hazard ratio of treat-
ment vs. placebo. Adverse events as defined by NCI CTCAE
v4.0 were summarized using descriptive statistics, where the
maximum grade for each type of toxicity was recorded for
each patient, and frequency tables were made to determine
toxicity patterns.
Results
Patient characteristics
Between January 2012 and September 2013 eighty men with
asymptomatic or minimally symptomatic CRPC were en-
rolled in this multicenter, double-blind phase II trial. Seventy
eight men (52 randomly assigned to tivantinib and 26 to
matching placebo) started treatment and were included in
safety and efficacy analysis. (Fig. 1) Groups were well bal-
anced for most baseline characteristics (Table 1). A higher
proportion of men self-identifying as African American and
men with lymph node involvement were randomized to pla-
cebo. There was no prior treatment with Radium-223,
enzalutamide or chemotherapy while nearly a third of patients
received prior abiraterone acetate and/or sipuleucel-T.
Efficacy
At the time of primary PFS analysis, 68 patients had
progressed and/or died (26/26 on placebo and 42/52 on
tivantinib). The median follow-up on event-free patients was
8.9 months (range: 2.3 to 19.6 months). The median PFS for
those on the placebo arm was 3.7 months (95% CI: 2.7 to
5.4 months) vs. a median PFS of 5.5 months for those treated
with tivantinib (95% CI: 3.2 to 8.0 months). (Fig. 2).
Fig. 4 Maximum Decline/
Minimum increase in PSA during
study
Fig. 3 Pulmonary metastasis
response to tivantinib
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A partial response by RECISTwas documented in 1 patient
randomized to tivantinib. (Fig. 3) Genomic profiling of this
individual with an exceptional response revealed high androgen
receptor amplification but no other significant alterations.PSA
increases were generally seen on both arms. (Fig. 4).
Crossover from placebo to tivantinib was allowed at the
time of progression. 12 of the 26 patients assigned to placebo
when they progressed received tivantinib. The median time on
tivantinib for this group was 4.3 months with a range of 2 to
10 months. One of the 12 experienced an objective partial
response by RECIST. Overall survival was not measured.
Safety
Toxicity is summarized in Table 2. Grade (G) 3 febrile neu-
tropenia was seen in 1 patient on tivantinib while G3 and 4
neutropenia was recorded in 1 patient each on tivantinib and
placebo. G3 sinus bradycardia was recorded in twomen on the
tivantinib arm. Eleven deaths (4 placebo and 7 tivantinib)
were recorded during the trial and were all determined to be
unrelated to therapy.
Discussion
Treatment with tivantinib was associated with minimal toxic-
ity and a significantly longer PFS when compared to placebo
Table 2 Grade 3+ Adverse Events regardless of attribution
*T (n = 52)
*P (n = 26)
Grade 3/4 Grade 5
Acute coronary syndrome T 1(2) 0(0)
P 0(0) 0(0)
Back Pain T 1(2) 0(0)
P 2(8) 0(0)
Confusion T 0(0) 0(0)
P 2(8) 0(0)
Death NOS T 1(2) 1(2)
P 0(0) 1(4)
Dehydration T 0(0) 0(0)
P 3(12) 0(0)
Duodenal ulcer T 1(2) 0(0)
P 0(0) 0(0)
Dyspnea T 1(2) 0(0)
P 0(0) 0(0)
Dizziness T 1(2) 0(0)
P 0(0) 0(0)
Fall T 0(0) 0(0)
P 1(4) 0(0)
Fatigue T 2(4) 0(0)
P 0(0) 0(0)
Gait disturbance T 0(0) 0(0)
P 1(4) 0(0)
Generalized muscle weakness T 0(0) 0(0)
P 1(4) 0(0)
Hypertension T 1(2) 0(0)
P 0(0) 0(0)
Hypokalemia T 0(0) 0(0)
P 1(4) 0(0)
Hyponatremia T 1(2) 0(0)
P 0(0) 0(0)
Hypotension T 0(0) 0(0)
P 1(4) 0(0)
Hypoxia T 1(2) 1(2)
P 0(0) 0(0)
Infections T 1(2) 0(0)
P 3(12) 0(0)
Musculoskeletal and connective
tissue disorder - Other
T 0(0) 0(0)
P 1(4) 0(0)
Neoplasms benign, malignant
and unspecified
T 0(0) 1(2)
P 1(4) 0(0)
Nervous system disorders – Other T 0(0) 0(0)
P 1(4) 0(0)
Pleural effusion T 0(0) 0(0)
P 1(4) 0(0)
Sinus bradycardia T 3(6) 0(0)
P 0(0) 0(0)
Sinus Tachycardia T 0(0) 0(0)
P 1(4) 0(0)
Table 2 (continued)
*T (n = 52)
*P (n = 26)
Grade 3/4 Grade 5
Syncope T 0(0) 0(0)
P 2(8) 0(0)
Thromboembolic event T 0(0) 0(0)
P 1(4) 0(0)
Tumor Pain T 1(2) 0(0)
P 0(0) 0(0)
Urinary tract obstruction T 0(0) 0(0)
P 1(4) 0(0)
Hematologic AE, no (%) Arm Grade 3 Grade 4
Anemia *T 3(6) 0(0)
*P 2(8) 0(0)
Febrile neutropenia T 1(2) 0(0)
P 0(0) 0(0)
Neutrophil count decreased T 1(2) 1(2)
P 1(4) 1(4)
Platelet count decreased T 1(2) 0(0)
P 0(0) 0(0)
White blood cell decreased T 1(2) 1(2)
P 2(8) 0(0)
*T = tivantinib, P = placebo
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in men with asymptomatic or minimally symptomatic
mCRPC. In comparing the PFS distributions between treat-
ment arms, the p-value for the log-rank test was p = 0.02.
Furthermore, this p-value reflects a two-sided alternative hy-
pothesis, which is more stringent than what was designed in
this trial. Tivantinib’s favorable side effect profile has been
demonstrated in various clinical trial settings, but these studies
failed to achieve their respective primary endpoints. [19–23]
This broad lack of efficacy is seen despite an underlying bio-
logic rationale that is similar to the current trial. Several factors
should be considered when interpreting the results of the pres-
ent trial. First, the strengths of our report include the random-
ized design, the use of PCWG2 guidelines to determine pro-
gression and the control arm performed as expected. However,
this study’s small size makes it more sensitive to biases that
are potentially unaccounted for. More troublesome is the un-
certainty of both the underlying mechanism of action of
tivantinib and the value of PFS as an important endpoint in
mCRPC trials. During the conduct of this trial, preclinical
studies reported tivantinib’s activity is not via the inhibition
of c-MET/HGF signaling. [16, 24] [25, 26] Rather, the in vitro
activity is more consistent with a cytotoxic agent. Targeting
MET therefore remains unproven as a strategy that produces
clinical benefit in men with mCRPC. [27]
The inability to rely on intermediate endpoints to predict
overall survival in mCRPC is problematic. [2, 28–30] This must
be considered when we interpret the significant improvement in
PFS seen in this study. The experience with cabozantinib’s de-
velopment in mCRPC is perhaps most instructive. [31]
Cabozantinib, a potent inhibitor of MET and VEGFR2, failed
to improve overall survival (OS) when compared with predni-
sone in heavily treated men with mCRPC. These negative phase
III results were accompanied by significant improvements in
bone scan response, radiographic PFS, circulating tumor cell
conversions, time to first symptomatic skeletal event and favor-
able bone biomarker changes. One potential explanation for the
lack of OS benefit is the high number of dose reductions and
discontinuations for toxicity. The phase II experience was asso-
ciated with unprecedented tumor regression in the majority with
soft tissue disease, normalization of bone scans in 12% and
improvement in bone pain in 67%. [32] This apparent paradox
seems most acute in advanced prostate cancer trials but it has
been seen in other tumor types and caution has been advised
when making conclusions with PFS data. [33]
Conclusion
Tivantinib has mild toxicity and significantly improved PFS
compared to placebo in men with asymptomatic/minimally
symptomatic mCRPC. The magnitude of benefit does not
support further evaluation as a single agent. Optimal further
development of tivantinib in mCRPC would ideally include a
better understanding of the drug’s underlying mechanism of
action. This would better inform combination studies with
other therapies in mCRPC.
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